The challenge of de‐labeling penicillin allergy

Abstract

Background Even though 8%‐25% of most populations studied globally are labeled as penicillin allergic, most diagnoses of penicillin allergy are made in childhood and relate to events that are either not allergic in nature, are low risk for immediate hypersensitivity, or are a potential true allergy that has waned over time. Penicillin allergy labels directly impact antimicrobial stewardship by leading to use of less effective and broader spectrum antimicrobials and are associated with antimicrobial resistance. They may also delay appropriate antimicrobial therapy and lead to increased risk of specific adverse healthcare outcomes. Operationalizing penicillin allergy de‐labeling into a new arm of antimicrobial stewardship programs (ASPs) has become an increasing global focus. Methods We performed an evidence‐based narrative review of the literature of penicillin allergy label carriage, the adverse effects of penicillin allergy labels, and current approaches and barriers to penicillin allergy de‐labeling. Over the period 1928‐2018 in Pubmed and Medline, search terms used included “penicillin allergy” or “penicillin hypersensitivity” alone or in combination with “adverse events,” “testing,” “evaluation,” “effects,” “label,” “de‐labeling,” “prick or epicutaneous,” and “intradermal” skin testing, “oral challenge or provocation,” “cross‐reactivity,” and “antimicrobial stewardship”. Results Penicillin allergy labels are highly prevalent, largely inaccurate and their carriage may lead to unnecessary treatment and inferior outcomes with alternative agents as well as adverse public health outcomes such as antibiotic resistance. Conclusions Operationalizing penicillin allergy de‐labeling as an aspect of ASP has become an increasing global focus. There is a need for validated approaches that optimally combine the use of history and ingestion challenge with or without proceeding formal skin testing to tackle penicillin allergy efficiently within complex healthcare systems. At the same time, there is great promise for penicillin allergy evaluation and de‐labeling as an individual and public health strategy to reduce adverse healthcare outcomes, improve antimicrobial stewardship, and decrease healthcare costs.

Progress in understanding hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs

“…Such re-evaluation is crucial considering the large number of patients who could be avoiding NSAIDs despite being no longer hypersensitive 119,120 as occurs with other drugs. 121,122 Whether tolerance persists or whether repetitive NSAIDs contacts could re-induce hypersensitivity is unknown. In addition, it is unclear whether patients maintaining NSAIDs hypersensitivity represent a different NIUA subphenotype and whether they would also lose hypersensitivity.…”

Impact of reported NSAID “allergies” on opioid use disorder in back pain

“…Previous work has clearly demonstrated that beta-lactam allergy labels directly impact antimicrobial stewardship by leading to use of broader spectrum, less effective antimicrobials and are associated with antimicrobial resistance, higher costs, and delays in care. 37 Our findings suggest that for patients with chronic back pain, having a reported NSAID allergy is associated with a higher risk of receiving other analgesic medications, including opioids. Many NSAIDs are available over-the-counter and less costly than alternative drugs such as opioids or tricyclic antidepressants.…”

Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries

“…Firstly, there were marginally more respondents who answered to do skin testing for cephalosporins than penicillins. This may be a reflection of the increasing use of cephalosporins in Asia and hence increase in DHR [59]; intermittent difficulties in accessing commercial PPL and minor determinants, and emerging safety data of direct amoxicillin oral provocation tests in low-risk patients without the need for prior skin testing [60]. Secondly, iodinated contrast media (ICM) has now emerged as one of the "new" drugs for which skin testing has become increasingly used, likely for several reasons.…”